ABT-384
- Generic Name
- ABT-384
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34F3N5O2
- CAS Number
- 868623-40-9
- Unique Ingredient Identifier
- R5TH77F919
- Background
ABT-384 has been used in trials studying the treatment of Alzheimer's Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 267
- Registration Number
- NCT01137526
- Locations
- 🇿🇦
Site Reference ID/Investigator# 45584, Belville, South Africa
🇷🇺Site Reference ID/Investigator# 37944, Moscow, Russian Federation
🇬🇧Site Reference ID/Investigator# 36327, Bath, United Kingdom
A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2010-12-14
- Lead Sponsor
- Abbott
- Target Recruit Count
- 12
- Registration Number
- NCT01009216
- Locations
- 🇺🇸
Site Reference ID/Investigator# 23882, Glendale, California, United States
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2010-11-03
- Lead Sponsor
- Abbott
- Target Recruit Count
- 28
- Registration Number
- NCT00968422
- Locations
- 🇺🇸
Site Reference ID/Investigator# 23024, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath